170 related articles for article (PubMed ID: 15930896)
1. Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats.
Hoving S; Seynhaeve AL; van Tiel ST; Eggermont AM; ten Hagen TL
Anticancer Drugs; 2005 Jul; 16(6):667-74. PubMed ID: 15930896
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats.
ten Hagen TL; Seynhaeve AL; van Tiel ST; Ruiter DJ; Eggermont AM
Int J Cancer; 2002 Jan; 97(1):115-20. PubMed ID: 11774252
[TBL] [Abstract][Full Text] [Related]
3. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats.
Ten Hagen TL; Van Der Veen AH; Nooijen PT; Van Tiel ST; Seynhaeve AL; Eggermont AM
Int J Cancer; 2000 Sep; 87(6):829-37. PubMed ID: 10956394
[TBL] [Abstract][Full Text] [Related]
4. Effect of low-dose tumor necrosis factor-alpha in combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats.
Hoving S; van Tiel ST; Eggermont AM; ten Hagen TL
Anticancer Res; 2005; 25(2A):743-50. PubMed ID: 15868905
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics.
Brouckaert P; Takahashi N; van Tiel ST; Hostens J; Eggermont AM; Seynhaeve AL; Fiers W; ten Hagen TL
Int J Cancer; 2004 Apr; 109(3):442-8. PubMed ID: 14961585
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
Gabizon AA
Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
[TBL] [Abstract][Full Text] [Related]
7. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma.
Skubitz KM
Cancer Invest; 2003 Apr; 21(2):167-76. PubMed ID: 12743981
[TBL] [Abstract][Full Text] [Related]
9. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.
van der Veen AH; de Wilt JH; Eggermont AM; van Tiel ST; Seynhaeve AL; ten Hagen TL
Br J Cancer; 2000 Feb; 82(4):973-80. PubMed ID: 10732774
[TBL] [Abstract][Full Text] [Related]
10. Lack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats.
ten Hagen TL; Hoving S; Ambagtsheer G; van Tiel ST; Eggermont AM
Br J Cancer; 2004 May; 90(9):1830-2. PubMed ID: 15208623
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet.
Nobuto H; Sugita T; Kubo T; Shimose S; Yasunaga Y; Murakami T; Ochi M
Int J Cancer; 2004 Apr; 109(4):627-35. PubMed ID: 14991586
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats.
de Wilt JH; Soma G; ten Hagen TL; Kanou J; Takagi K; Nooijen PT; Seynhaevel AL; Eggermont AM
Anticancer Res; 2000; 20(5B):3491-6. PubMed ID: 11131652
[TBL] [Abstract][Full Text] [Related]
13. Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation.
Ahmed M; Monsky WE; Girnun G; Lukyanov A; D'Ippolito G; Kruskal JB; Stuart KE; Torchilin VP; Goldberg SN
Cancer Res; 2003 Oct; 63(19):6327-33. PubMed ID: 14559820
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.
Hoving S; Brunstein F; aan de Wiel-Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL
Cancer Res; 2005 May; 65(10):4300-8. PubMed ID: 15899822
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density.
Wang Y; Gonzalez M; Cheng C; Haouala A; Krueger T; Peters S; Decosterd LA; van den Bergh H; Perentes JY; Ris HB; Letovanec I; Debefve E
Lasers Surg Med; 2012 Apr; 44(4):318-24. PubMed ID: 22362489
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
17. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
[TBL] [Abstract][Full Text] [Related]
18. Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas.
Rossi CR; Mocellin S; Pilati P; Foletto M; Campana L; Quintieri L; De Salvo GL; Lise M
Ann Surg Oncol; 2005 May; 12(5):398-405. PubMed ID: 15915374
[TBL] [Abstract][Full Text] [Related]
19. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2.
Cabanes A; Even-Chen S; Zimberoff J; Barenholz Y; Kedar E; Gabizon A
Clin Cancer Res; 1999 Mar; 5(3):687-93. PubMed ID: 10100723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]